Infectious Disease Diagnostics Market

Infectious diseases are caused by organisms such as bacteria, virus, fungi, and parasites and are capable of transmission from one species to another species. Infectious diseases spread from person to person either through direct contact or indirectly through insect bites or other vectors like food, soil, water, and air. Diagnosis of these diseases involves identifying the pathogen and its type and then diagnose infection has spread. Diagnosis is the initial step of discovering a disease and its treatment leads to elimination of infectious diseases. Infectious diseases are among the leading causes of morbidity and death. Diagnostics plays important part in deciding the course of any clinical treatment. While Infectious diseases diagnostics help in diagnosing disease caused because of pathogenic disease Infectious diseases such as HIV, tuberculosis, malaria, and Influenza are highly prevalent and can be efficiently diagnosed with the help of diagnostic tests available for the respective diseases. Traditional infectious disease diagnosis was time-consuming. Because of this factor, the Infectious Disease Diagnostics Market has seen the emergence of rapid, accurate, and portable point-of-care testing products. Point of care testing helps for faster diagnosis of infectious diseases nearby to the patient's location and provides immediate results. Several researchers are now working on multiplex point-of-care diagnostic technologies. Technologies utilized by these diagnostic tests are classified into biochemical techniques, molecular techniques, immunodiagnostics, conventional culturing, and staining techniques. Biochemical techniques include Enzyme-linked Immunosorbent Assay (ELISA), agglutination, and others, while molecular techniques include Polymerase Chain Reaction (PCR) and Next-Generation Sequencing techniques. These tests are capable of diagnosing the infectious diseases accurately with high throughput capacity.

Market Dynamics

Increasing prevalence of Infectious Disease Diagnostics Market is expected to drive the market growth over the forecast period, due to growing awareness for the early disease diagnostics. For instance, In 1995, According to the Centers for Disease Control and Prevention {CDCP}, Hospital-acquired infections( HAIs) in American hospitals are responsible for 1.7 million infections and 99,000 deaths occur per year. Out of all, the urinary tract infections occurs up to 32% of all the healthcare-acquired infections, followed by surgical site infections [22%], pneumonia [15%], and bloodstream infections [14%].

Key features of the study

• This report provides in-depth analysis of the global infectious disease diagnostics market and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024, as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
• It profiles leading players in the global infectious disease diagnostics market based on the following parameters -company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Becton Dickinson & Company, Cepheid, Inc., Abbott Laboratories, BioMerieux SA, Hologic, Inc., Danaher Corporation, Thermo Fisher Scientific, Inc., Roche Diagnostics, Alera Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.
• Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
• Global infectious disease diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Market Segmentation

• Technology Insights (Revenue, USD Mn & KT, 2025 - 2032)
• ELISA
• Polymerase Chain Reaction
• Immunoassays
• Cell Cultures
• Others
• Disease Indication Insights (Revenue, USD Mn & KT, 2025 - 2032)
• Central nervous system (CNS) Infection
• Meningitis
• Brain Abscess
• Diarrheal Disease
• Shigellosis
• Cholera
• Enteric/Typhoid Fever
• Respiratory Infections
• Tuberculosis
• Influenza
• Bronchitis
• Blood Infections
• Malaria
• Dengue
• Infectious Mononucleosis
• Others
• STDs
• Chlamydia
• AIDS
• Syphilis
• Others
• End User Insights (Revenue, USD Mn & KT, 2025 - 2032)
• Hospitals
• Diagnostics centers
• Dermatology Clinics
• Others (Research Institutes, Specialty Centres, etc.)
• Regional Insights (Revenue, USD Mn & KT, 2025 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa
• GCC Countries
• Israel
• Rest of Middle East & Africa
• Key Players Insights
• Becton Dickinson & Company
• Cepheid, Inc
• Abbott Laboratories
• BioMerieux SA
• Hologic, Inc
• Danaher Corporation
• Thermo Fisher Scientific, Inc
• Roche Diagnostics
• DiaSorin S.p.A
• Quidel Corporation
• Bio-Rad Laboratories

Show more